Detalhe da pesquisa
1.
Meaningful Change Thresholds and Fatigue Severity Points on Patient-Reported Outcomes by the Fatigue Symptoms and Impacts Questionnaire in Patients With Relapsing Multiple Sclerosis.
Value Health
; 27(5): 598-606, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38401796
2.
The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial.
Mult Scler
; 29(3): 427-435, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36550636
3.
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant.
Health Qual Life Outcomes
; 21(1): 40, 2023 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37158911
4.
Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).
Qual Life Res
; 32(11): 3053-3061, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439961
5.
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.
Am J Geriatr Psychiatry
; 30(5): 541-556, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34750057
6.
Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression.
Acta Psychiatr Scand
; 143(3): 253-263, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33249552
7.
Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure.
Value Health
; 22(8): 906-915, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31426932
8.
Humanistic outcomes in treatment resistant depression: a secondary analysis of the STAR*D study.
BMC Psychiatry
; 18(1): 352, 2018 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30373547
9.
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.
CNS Drugs
; 36(6): 649-658, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35441931
10.
Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray.
J Patient Rep Outcomes
; 6(1): 74, 2022 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35816217
11.
U.S. Food and Drug Administration's Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant Depression.
Ther Innov Regul Sci
; 56(1): 38-46, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34623613
12.
Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression.
Neuropsychiatr Dis Treat
; 18: 1127-1132, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35707064
13.
Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.
Int J Methods Psychiatr Res
; 31(4): e1927, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35749277
14.
A novel disease specific scale to characterize the symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis: A real-world study.
Mult Scler Relat Disord
; 59: 103637, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35168093
15.
SIBAT-A Computerized Assessment Tool for Suicide Ideation and Behavior: Development and Psychometric Properties.
Innov Clin Neurosci
; 19(4-6): 36-47, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35958973
16.
Development of a novel patient-reported outcome measure to assess signs and symptoms of COVID-19.
J Patient Rep Outcomes
; 6(1): 85, 2022 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35904710
17.
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
J Affect Disord
; 281: 767-775, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33261932
18.
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
CNS Drugs
; 35(7): 781-794, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34235612
19.
Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study.
Psychiatry Res
; 293: 113376, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32818917
20.
Suicide Ideation and Behavior Assessment Tool (SIBAT): Evaluation of Intra- and Inter-Rater Reliability, Validity, and Mapping to Columbia Classification Algorithm of Suicide Assessment.
Psychiatry Res
; 294: 113495, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33068913